Very recently, a CF patient homozygous for the nonsense mutation W1282X, a C-terminal CFTR mutation that results in a truncated protein with partial activity, was subjected to treatment with ivacaftor, resulting in therapeutic benefit. This evidence concerns the gene CFTR and cystic fibrosis.